Harrod-Kim Paul
Division of Vascular and Interventional Radiology, Department of Imaging Sciences, University of Rochester, Box 648, 601 Elmwood Avenue, Rochester, New York 14642, USA.
J Vasc Interv Radiol. 2006 Sep;17(9):1441-8. doi: 10.1097/01.RVI.0000231977.49263.DE.
Photodynamic therapy (PDT) has been used to treat cancer for more than 25 years. Although the focus has been primarily on surface or superficial lesions, there has been a rapid growth in its application to the treatment of deeper parenchymal malignancies. The photochemical reaction consists of a photosensitizer, which, when irradiated by light at a specific wavelength, generates a cytotoxic oxygen singlet. The end result is an efficient induction of cell death, primarily through apoptosis, microvascular damage, and an antitumor immune response. PDT is currently being used in the treatment of many cancers including lung cancer, head and neck cancers, liver metastases, cholangiocarcinoma, and prostate cancer. The growing body of evidence concerning its efficacy, the increasing use of imaging to guide PDT, and the innate minimally invasive characteristics of PDT suggest that it should become an important addition to the growing array of techniques in interventional oncology.
光动力疗法（PDT）用于治疗癌症已有25年以上。尽管主要聚焦于体表或浅表病变，但它在深部实质恶性肿瘤治疗中的应用迅速增长。光化学反应由一种光敏剂组成，当用特定波长的光照射时，会产生细胞毒性单线态氧。最终结果是主要通过凋亡、微血管损伤和抗肿瘤免疫反应有效诱导细胞死亡。目前，PDT正用于治疗多种癌症，包括肺癌、头颈癌、肝转移瘤、胆管癌和前列腺癌。关于其疗效的证据越来越多，用于指导PDT的成像技术使用日益增加，以及PDT固有的微创特性表明，它应成为介入肿瘤学中不断增加的技术手段的重要补充。
